Edition:
India

Allogene Therapeutics Inc (ALLO.OQ)

ALLO.OQ on NASDAQ Stock Exchange Global Select Market

27.96USD
1:30am IST
Change (% chg)

$0.03 (+0.11%)
Prev Close
$27.93
Open
$28.24
Day's High
$28.72
Day's Low
$27.76
Volume
67,307
Avg. Vol
166,002
52-wk High
$35.55
52-wk Low
$22.20

Latest Key Developments (Source: Significant Developments)

Allogene Therapeutics Reports Second Quarter 2019 Financial Results
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Allogene Therapeutics Inc ::ALLOGENE THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.41.Q2 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA.SEES FULL-YEAR 2019 NET LOSSES TO BE BETWEEN $200 MILLION AND $210 MILLION.ALLOGENE THERAPEUTICS - AS OF JUNE 30, ALLOGENE HAD $650.2 MILLION IN CASH, CASH EQUIVALENTS, AND INVESTMENTS, VERSUS $721.4 MILLION AS OF DECEMBER 31, 2018.  Full Article

Allogene Therapeutics Reports Q4, FY2018 Results
Friday, 8 Mar 2019 

March 8 (Reuters) - Allogene Therapeutics Inc ::ALLOGENE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.37.Q4 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.PHASE 1 ALLO-501 CLINICAL TRIAL ON-TRACK FOR INITIATION IN 1H 2019.EXPECTS FULL YEAR 2019 NET LOSSES TO BE BETWEEN $200 MILLION AND $210 MILLION.AS OF DECEMBER 31, 2018, ALLOGENE HAD $721.4 MILLION IN CASH, CASH EQUIVALENTS, AND INVESTMENTS.ON TRACK TO FILE AN IND APPLICATION IN 2019 FOR ALLO-715.  Full Article

Allogene Therapeutics in collaboration with Servier, announces FDA clearance of the Ind For Allo-501, an anti-Cd19 Allogeneic Car T (Allocar T) therapy
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Allogene Therapeutics Inc ::ALLOGENE THERAPEUTICS, IN COLLABORATION WITH SERVIER, ANNOUNCES FDA CLEARANCE OF THE IND FOR ALLO-501, AN ANTI-CD19 ALLOGENEIC CAR T (ALLOCAR T) THERAPY.ALLOGENE THERAPEUTICS - ALPHA PHASE 1 TRIAL TO TREAT UP TO 24 PATIENTS & IS ON TRACK FOR INITIATION IN H1 2019.ALLOGENE THERAPEUTICS - TO INITIATE ALPHA STUDY FOR ALLO-501 IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA.ALLOGENE THERAPEUTICS - ALLO-647, ALLOGENE'S PROPRIETARY ANTI-CD52 ANTIBODY, TO BE ADMINISTERED AS PART OF LYMPHODEPLETION REGIMEN.  Full Article